Abstract
The stereocontrolled construction of biologically relevant chromanones and tetrahydroxanthones has been achieved through the addition of alkynes to benzopyrylium trilfates under the influence of copper bis(oxazoline) catalysis. Excellent levels of enantiocontrol (63–98% ee) are achieved in the addition of a variety of alkynes to an array of chromenones with a hydrogen in the 2-position. Promising levels of enantiocontrol (54–67% ee) are achieved in the alkynylation of chromenones with esters in the 2-position, generating tertiary ether stereocenters re- sembling those frequently found in naturally occurring metabolites.
Keywords: asymmetric catalysis, heterocycles, natural products, synthetic design, synthetic methods
Naturally occurring chromanones and tetrahydroxanthones frequently possess attractive biological properties, including anticancer, antibacterial, and antifungal activity (Figure 1).[1] These molecules, existing in both monomeric and dimeric forms, often present significant synthetic challenges. One aspect contributing to their difficult synthesis is the 2-stereocenter (for the purposes of this manuscript, a chromanone numbering scheme has been adopted, Figure 1). Given the frequency with which the 2-stereocenter emerges in several families of bioactive chromenones and tetrahydroxanthones, there has been significant interest in learning how to create this bond with high levels of enantiocontrol.[2]
Figure 1.

Select bioactive chromanones and tetrahydroxanthones.
In the context of natural product synthesis, there are only a limited number of strategies with demonstrated success. Porco has shown a racemic siloxyfuran addition to benzopyrylium triflates followed by a sequence that includes a Birman resolution can be a productive approach to synthesizing tetrahydroxanthones with excellent levels of enantiomeric excess (Scheme 1A).[3] Tietze uses an intramolecular Wacker reaction to control the formation of the 2-stereocenter and several steps are required to convert the alkene to the desired chromanone natural product (Scheme 1B).[4] Despite the success of these tactics, a direct and general method for the installation of the 2-stereocenter remains a lucrative pursuit. Our group has been interested in learning how to synthesize the 2-stereocenter of chromenones with enantiocontrol. Our efforts initially focused on the addition of silyl ketene acetals to benzopyrylium triflates, reactive species generated in situ from chromenones and silyl triflates.[5] Initially inspired by Porco’s success, we took advantage of silanediol anion-binding catalysis to con- trol, for the first time, addition reactions of silyl ketene acetals to benzopyrylium triflates affording 2-alkyl chromanones in up to 57% enantiomeric excess (Scheme 1D).[6] We were delighted to see MancheÇo and co-workers further improved upon these findings, obtaining greater than 90% enantiomeric excess under the influence of her triazolium catalysts with select substrates.[7] Despite the promise of anion-binding catalysis, the synthesis of tertiary ether 2-chromanones in high enantiomeric excess directly from chromone precursors remains a topic of great interest.
Scheme 1.

Methods for synthesis of chromanones with a chiral tertiary ether stereocenter.
Considering the limitations of anion-binding catalysis (Table 1), we expanded our investigations to other catalytic platforms for controlling addition reactions to chromone, such as alkynylation.[8] We hypothesized that copper bis(oxazoline)[9] complexes would influence the enantioselective addition of terminal acetylides onto benzopyrylium triflates (Scheme 1E). This reasoning was inspired by Watson’s work demonstrating that copper acetylides undergo addition to in situ-generated oxocarbenium ions with high levels of enantiomeric excess when a bis(oxazoline) ligand was present.[10] While this manuscript was under preparation, Aponick and co-workers recently reported enantioselective alkynylation of chromones with their StackPhos ligands (Scheme 1C).[11] Herein, we describe our findings of copper bis(oxazoline) catalysis as an excellent platform for the reaction of terminal alkynes and unhindered benzopyrylium triflates (R=H) to generate desirable products with excellent levels of enantiocontrol. This method represents a more practical approach because it requires readily accessible bis(oxazoline) ligands. Furthermore, we have found that copper bis(oxazoline) catalysis provides promising levels of enantiocontrol in the addition of terminal acetylides to substi- tuted benzopyrylium triflates (R=esters) to create chroma- nones with highly substituted 2-stereocenters.
Table 1.
Optimization.
![]() | |||||
|---|---|---|---|---|---|
| Entry[a] | Copper source | Ligand R’’, R’ | Silyl triflate |
Yield [%][b] | ee [%] |
| 1 | Cu(OTf)2 | Me, Bn (5a) | TBSOTf | 44 | 14 |
| 2 | CuOTf | Me, Bn (5a) | TBSOTf | 40 | 16 |
| 3 | CuBr | Me, Bn (5 a) | TBSOTf | 41 | 14 |
| 4 | Cul | Me, Bn (5a) | TBSOTf | 69 | 95 |
| 5 | Cul | Me, Ph (5 b) | TBSOTf | 85 | 86 |
| 6 | Cul | Me, iPr (5 c) | TBSOTf | 64 | 93 |
| 7 | Cul | Me, tBu (5d) | TBSOTf | 92 | 70 |
| 8 | Cul | Me, Bn (5 a) | TMSOTf | 68 | 94 |
| 9 | Cul | Me, Bn (5 a) | TlPSOTf | 87 | 91 |
| 10 | Cul[c] | Me, Bn (5 a) | TBSOTf | 72 | 97 |
| 11 | Cul[d] | Me, Bn (5 a) | TBSOTf | 73 | 94 |
| 12 | Cul[e] | Me, Bn (5 a) | TBSOTf | 76 | 84 |
See the Supporting Information for detailed procedures.
NMR yields.
Reaction conducted in a single flask with o-xylenes.
5 mol% catalyst loading, o-xylenes as the solvent.
1 mol% catalyst loading, o-xylenes as the solvent.
Our investigations were initiated with the addition of phenyl acetylene to benzopyrylium triflate 2, generated in situ from 1, in the presence of a suitable copper source and ligand (Table 1). During a systematic investigation of the reaction parameters it was found that the nature of the copper source, bis(oxazoline) ligand, and silyl triflate significantly affected the outcome of the reaction with respect to both yield and enantioselectivity. Cu(OTf)2, CuOTf, and CuBr gave rise to 4 with yields between 40–44% and low enantiomeric excess (Table 1, entries 1–3). CuI was identified as the best reagent for this process, producing 4a with 69% yield and 95% enantiomeric excess (entry 4). The screening of several bis(oxazoline) ligands demonstrated the enantiomeric excess and yield were readily influenced by the structure of the ligand. The highest enantiomeric excess was realized with ligand 5a (R′=Bn, 95% ee, entry 4). Lower enantiomeric excesses were observed with ligands 5b, 5c, and 5d (R′ = Ph, iPr, tBu, respectively) but the yields were higher in some cases (entries 4–7). Finally, the silyl triflate employed in the reaction had a small influence on the yield and stereocontrol. Specifically, tert-butyldimethylsilyl triflate (TBSOTf) gave rise to the best enantiomeric excess when compared to trimethylsilyl triflate (TMSOTf) and triispropylsilyl triflate (TIPSOTf) (entries 4, 8–9).
The yield of the reaction was improved from 69 to 72% by conducting the reaction in a single flask, the enantiomeric excess remained excellent at 97% (Table 1, entry 10). The reduction of the catalyst loading from 10 to 5 mol% and 1 mol% resulted in small losses in enantiomeric excess (entries 11–12).
After having identified a promising set of reaction conditions for the enantioselective alkynylation of chromenone 1, the scope of the reaction with respect to chromenone and alkyne was tested. First, the substituents on the alkyne were probed (Table 2). A variety of aryl acetylides were found to operate well in the reaction regardless of their substitution pattern. For instance, nearly identical enantiomeric excesses were observed for phenyl acetylene, p-methoxy phenyl acetylene, p-trifluoromethyl phenyl acetylene, p-methyl phenyl acetylene, p-chloro phenyl aceytene, and m-methyl phenyl acetylene (Table 2, entries 1–6). The sterically encumbered o-methyl phenyl acetylene gave rise to product 4g in 67% yield and 82% enantiomeric excess (entry 7). Alkynes containing non-aryl substituents (R=TMS, alkyl, vinyl) were also accommodated in the reaction (entries 8–12), although optimal yields and stereocontrol was achieved with different bis(oxazoline) ligands (entries 8–10). For example, trimethylsilyl acetylene, a reaction partner of interest in the context of tetrahydroxanthone synthesis, afforded product 4h in 86% yield and 95% enantiomeric excess under the influence of bis(oxazoline) 5d (entry 8). Synthetically relevant chromanone products 4i and 4j were also produced in high yield and high enantiomeric excess in the presence of ligands 5e and 5 f, respectively (entries 9 and 10).
Table 2.
Alkyne substrate scope.
![]() | ||||
|---|---|---|---|---|
| Entry[a] | Alkyne R= | 4 | Yield [%][b] | ee [%] |
| 1 | Ph | 4 a | 98 | 97 |
| 2 | p-MeOPh | 4 b | 63 | 96 |
| 3 | p-CF3Ph | 4 c | 85 | 97 |
| 4 | p-tolyl | 4 d | 83 | 96 |
| 5 | p-ClPh | 4 e | 86 | 97 |
| 6 | m-tolyl | 4 f | 82 | 97 |
| 7 | o-tolyl | 4 g | 67 | 82 |
| 8[c] | TMS | 4 h | 86 | 95 |
| 9[d] | CH2OBn | 4 i | 85 | 85 |
| 10[e] | CH2CH2OBn | 4 j | 96 | 85 |
| 11 | cyclopropyl | 4 k | 45 | 82 |
| 12 | 1-cyclohexenyl | 4 l | 50 | 71 |
See the Supporting Information for detailed procedures.
Isolated yields.
Ligand 5d was used.
Ligand 5e (R’=Ph, R″=Bn) was used.
Ligand 5 f (R′=2-naphthyl, R″=Bn) was used. (S)-Enantiomer was obtained.
Chromones with substituents on the 5-, 6-, 7-, and 8-positions were generally well tolerated, yielding corresponding 2-(phenylethynyl)chromanones in high enantiomeric excess. (Scheme 2). Chromenones with a variety of substituents in the 6-position (e.g., R=CF3, CH3, F, Cl, Br) performed well in the reaction giving rise to products 4m–q in excellent yield and enantiomeric excess. Donating substituents in the 7-position enabled formation of the desired products 4r–s with excellent enantiomeric excess but with reduced yield. 8-Phenyl chromenone (1t), was also a competent reaction partner affording 4t with 93% yield and 84% enantiomeric excess. The naturally-in- spired substitution pattern on chromenone 1u was also easily incorporated into the reaction platform generating product 4u in 75% yield and with 93% ee. Moderate enantiomeric excess was obtained in the case of 3-(p-tolyl) chromone 1v, which yielded 4v as a 2:1 mixture of diastereomers in 63% ee.
Scheme 2.

Chromenone substrate scope. See the Supporting Information for detailed procedures.
The relevance of the methodology to natural product con- struction was tested in the synthesis of chromanones 6–7 and tetrahydroxanthone 9 (Scheme 3). The partial hydrogenation of the alkyne in chromanone 4a was easily achieved with a Pd/CaCO3, Pb catalyst system, 3,6-dithia-1,8-octanediol, and H2 to afford chromanone 6 in excellent yield with no loss in enantiomeric excess (Scheme 3A). Under the influence of Pd/CaCO3, Pb, and H2, the synthesis of 7 was affected in 84% yield with no loss in enantiomeric excess. The application of the methodology to the synthesis of tetrahydroxanthones is depicted in Scheme 3B. Chromanone 4w is prepared in 77% yield and excellent enantiomeric excess (92% ee) under the influence of CuI and ligand 5d. Silyl group deprotection in the presence of cesium fluoride (CsF), insertion of ethyldiazoacetate into the terminal alkyne C—H bond,[12] and hydrogenation of the intermediate allene gives rise to 8 in 40% yield and 90% ee over three steps. Tetrahydroxanthone formation is achieved by a Lewis acid promoted intramolecular Dieckmann cyclization to yield 9.[4b] The final cyclization step does erode the enantiomeric excess slightly and investigations are ongoing to overcome this issue.
Scheme 3.

Demonstration of methodology in chromanone and tetrahydroxanthone synthesis. See the Supporting Information for detailed procedures.
The high levels of enantiocontrol and extensive substrate scope observed in the synthesis of 2-H chromanones 4a–w inspired us to stress the limits of the reaction system in the synthesis of more highly substituted stereogenic centers. Specifically, it was envisioned that chromenones containing esters in the 2-position would render the methodology even more valuable in the context of naturally occurring tetrahydroxanthone synthesis by enabling the enantioselective construction of tertiary ether stereocenters. The reaction was put to the test with the addition of phenyl acetylene to chromone-2-carboxylate esters (Table 3). We were delighted to find an initial enantiomeric excess of 34% with the bis(oxazoline) ligand 5a containing a benzyl group (R=Bn, Table 3, entry 1). A quick screen of other readily available bis(oxazoline) ligands resulted in the identification of tBu as the best substituent identified to date with respect to both the yield and enantiomeric excess (entry 3). Upon cooling the reaction from 0 to −28 °C a very encouraging 67% enantiomeric excess was observed (entry 4). Ethyl, iso-propyl, and tert-butyl chromone-2-carboxylate esters were also tolerated but with reduced enantiomeric excess (entries 5–7).
Table 3.
Tertiary ether stereocenter formation.
![]() | |||||
|---|---|---|---|---|---|
| Entry[a] | Ligand R’ = | R= | T [°C] | Yield [%] | ee [%] |
| 1[b] | Bn (5 a) | Me | 0 | 29 | 34 |
| 2[b] | Ph (5 b) | Me | 0 | 86 | 15 |
| 3[b] | tBu (5d) | Me | 0 | 87 | −38 |
| 4 | tBu (5d) | Me | −78 to −28 | 87 | −67 |
| 5 | tBu (5d) | Et | −78 to −28 | 91 | −65 |
| 5 | tBu (5d) | iPr | −78 to −28 | 88 | −54 |
| 7 | tBu (5d) | tBu | −78 to −28 | 15 | −60 |
See the Supporting Information for detailed procedures.
Conducted in a two-step process in toluene, see procedure 1 in the Supporting Information for details.
In conclusion, copper bis(oxazoline) complexes have proven to be easy to use, general catalyst systems for the synthesis of 2-stereogenic centers found in biologically relevant chromanones. Excellent levels of enantiocontrol can be achieved in the reaction of a diverse array of chromenone and alkyne reaction partners, generating desirable 2-ethynyl chromanone products in high yield. The reaction system can also be extended to the synthesis of more highly substituted 2-stereogenic centers that may have direct applications in naturally occurring bioactive chromanone and tetrahydroxanthone synthesis. Our current efforts, directed toward the continued exploration of these reactions in the synthesis of naturally occurring dimeric tetrahydroxanthones, will be reported as soon as possible.
Experimental Section
General method
To an 8 mL screw-top vial was added chromone (29.2 mg, 0.2 mmol, 1.0 equiv), CuI (3.8 mg, 0.02 mmol, 10 mol%), (S)-Bn-BOX (8.8 mg, 0.024 mmol, 12 mol%), o-xylene (2 mL), iPr2NEt (52.3 mL, 0.3 mmol, 1.5 equiv), and phenyl acetylene (28.6 mL, 0.26 mmol, 1.3 equiv) in that order at room temperature. This mixture was then allowed to stir for 30 min. The vial was purged with dry N2 and then cooled to −78 °C. TBSOTf (60 mL, 0.26 mmol, 1.3 equiv) was added at −78 °C, and then the reaction was transferred to the lab freezer at −28 °C and allowed to react for 48 h. The reaction was quenched by the addition of 6n HCl (2 mL) and stirred for 2 h. The reaction mixture was extracted with EtOAc (3×2 mL), washed with saturated NaHCO3 solution, dried over anhydrous NaSO4, and the solvent removed under vacuum to obtain the crude product. The crude product was purified by column chromatography on silica gel with hexane:EtOAc (9:1) to afford an off-white solid (48.8 mg, 98% yield, 97% ee).
Supplementary Material
Acknowledgements
The National Institutes of Health are gratefully acknowledged for providing funds for our studies (5 R35 GM124804).
Footnotes
Conflict of interest
The authors declare no conflict of interest.
Supporting information and the ORCID identification number(s) for the author(s) of this article can be found under: https://doi.org/10.1002/chem.201904822.
References
- [1].a) For recent reviews on dimeric chromanones and tetrahydroxanthones, see:Wezeman T, Brase S, Masters K, Nat. Prod. Rep 2015, 32, 6–28; [DOI] [PubMed] [Google Scholar]; b) Masters K, Brase S, Chem. Rev 2012, 112, 3717–3776; for isolation and biological activities of gontyolides, see: [DOI] [PubMed] [Google Scholar]; Kikuchi H, Isobe M, Sekiya M, Abe Y, Hoshikawa T, Ueda K, Kurata S, Katou Y, Oshima Y, Org. Lett 2011, 13, 4624–4627; for isolation and biological activities of phomoxanthone A, see: [DOI] [PubMed] [Google Scholar]; c) Isaka M, Jaturapat A, Rukserre K, Damwiset-kanjana K, Tanticharoen M, Thebtaranonth Y, J. Nat. Prod 2001, 64, 1015–1018; [DOI] [PubMed] [Google Scholar]; d) Rçnsberg D, Debbab A, Mandi A, Vasylyeva V, Bohler P, Stork B, Engelke L, Hamcher A, Sawadogo R, Diederich M, Wray V, Lin W, Kassack M, Janiak C, Scheu S, Wesselborg S, Kurtan T, Aly A, Proksch P, J. Org. Chem 2013, 78, 12409–12425; for isolation and biological activities of the blennolides, see: [DOI] [PubMed] [Google Scholar]; Zhang W, Krohn K, Zia-Ullah U Pescitelli Florke, G., Di Bari L, Antus S, Kurtan T, Rheinheimer J, Draeger S, Schulz B, Chem. Eur. J 2008, 14, 4913–4923; for isolation and biological data on the dicerandrols, see: [DOI] [PubMed] [Google Scholar]; Wagenaar MM, Clardy J, J. Nat. Prod 2001, 64, 1006–1009. [DOI] [PubMed] [Google Scholar]
- [2].For a review, see:Nibbs AE, Scheidt KA, Eur. J. Org. Chem 2012, 449–462; for select examples of enantioselective 2-alkylchromanone synthesis, see: [DOI] [PMC free article] [PubMed] [Google Scholar]; a) Rao AV, Gaitonde AS, Prakash SP, Rao SP, Tetrahedron Lett. 1994, 35, 6347–6350; [Google Scholar]; b) Kawasaki M, Kakuda H, Goto M, Kawabata S, Kometani T, Tetrahedron: Asymmetry 2003, 14, 1529–1534; [Google Scholar]; c) Biddle MM, Lin M, Scheidt KA, J. Am. Chem. Soc 2007, 129, 3830–3831; [DOI] [PubMed] [Google Scholar]; d) Boekl H, Mackert R, Muramann C, Schweickert N US66646136B1, 2013; [Google Scholar]; e) Termath AO, Sebode H, Schlundt W, Stemmler RT, Netscher T, Bonrath W, Schmalz H-G, Chem. Eur. J 2014, 20, 12051–12055; [DOI] [PubMed] [Google Scholar]; f) Brown MK, Degrado SJ, Hoveyda AH, Angew. Chem. Int. Ed 2005, 44, 5306–5310; Angew. Chem. 2005, 117, 5440 – 5444; [DOI] [PubMed] [Google Scholar]; g) Vila C, Hornillos V, Fananas-Mastral M, Feringa BL, Chem. Commun 2013, 49, 5933–5935; [DOI] [PubMed] [Google Scholar]; h) Trost BM, Gnanamani E, Kalnmals CA, Hung C-I, Tracy JS, J. Am. Chem. Soc 2019, 141, 1489–1493. [DOI] [PubMed] [Google Scholar]
- [3].a) Qin T, Iwata T, Ransom TT, Beutler JA, Porco JA, J. Am. Chem. Soc 2015, 137, 15225–15233; [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Qin T, Porco JA, Angew. Chem. Int. Ed 2014, 53, 3107–3110; Angew. Chem. 2014, 126, 3171 –3174. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [4].a) Tietze LF, Ma L, Reiner JR, Jackenkroll S, Heidemann S, Chem. Eur. J 2013, 19, 8610–8614; [DOI] [PubMed] [Google Scholar]; b) Ganapathy D, Reiner JR, Valdomir G, Senthilkumar S, Tietze LF, Chem. Eur. J 2017, 23, 2299–2302. [DOI] [PubMed] [Google Scholar]
- [5].a) Iwasaki H, Kume T, Yamamoto Y, Akiba K, Tetrahedron Lett. 1987, 28, 6355–6358; [Google Scholar]; b) Stubbing LA, Li FF, Furkert DP, Caprio VE, Brimble MA, Tetrahedron 2012, 68, 6948–6956; [Google Scholar]; c) Liu J, Li Z, Tong P, Xie Z, Zhang Y, Li Y, J. Org. Chem 2015, 80, 1632–1643. [DOI] [PubMed] [Google Scholar]
- [6].Hardman-Baldwin AM, Visco MD, Wieting JM, Stern C, Kondo S, Mattson AE, Org. Lett 2016, 18, 3766–3769. [DOI] [PubMed] [Google Scholar]
- [7].Fischer T, Bamberger J, Gomez-Martinez M, Piekarski D, Manche-Ço OG, Angew. Chem. Int. Ed 2019, 58, 3217–3221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [8].a) Eriksson M, Iliefski T, Nilsson M, Olssen T, J. Org. Chem 1997, 62, 182–187; [DOI] [PubMed] [Google Scholar]; b) Daia DE, Gabbut CD, Heron BM, Hepworth JD, Hursthouse MB, Malik KMA, Tetrahedron Lett. 2003, 44, 1461–1464. [Google Scholar]
- [9].For a review on chiral bis(oxazoline) ligands in asymmetric catalysis, see: Desimoni G, Faita G, Jorgensen KA, Chem. Rev 2006, 106, 3561–3651. [DOI] [PubMed] [Google Scholar]
- [10].Srinivas HD, Maity P, Yap GPA, Watson MP, J. Org. Chem 2015, 80, 4003–4016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- [11].DeRatt LG, Pappoppula M, Aponick A, Angew. Chem. Int. Ed 2019, 58, 8416–8420. [DOI] [PubMed] [Google Scholar]
- [12].Suárez A, Fu GC, Angew. Chem. Int. Ed 2004, 43, 3580–3582; Angew. Chem. 2004, 116, 3664 –3666. [DOI] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.



